Gilead lines up a $1.55B biotech buy­out deal as CEO Dan O’Day in­vests in his lat­est can­cer block­buster dream

The Gilead BD team has teed up an­oth­er on­col­o­gy deal for CEO Dan O’Day.

This time the big biotech is rolling out a $300 mil­lion cash in­vest­ment in Tizona Ther­a­peu­tics in South San Fran­cis­co, buy­ing up 49.9% of the com­pa­ny and re­serv­ing up to $1.25 bil­lion more to swal­low the whole en­chi­la­da if the biotech’s am­bi­tious Phase I pro­gram for their HLA-G drug TTX-080 pans out as hoped for.

The deal is square­ly fo­cused on this one drug, which Tizona CEO Scott Clarke has billed as a bright new hope for treat­ing tu­mors that es­cape the cur­rent gen­er­a­tion of PD-(L)1 drugs in or near the mar­ket. And it’s not their lead.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER